Dominant-Negative Mutation of p53 Tumor Suppressor Gene in Endometrial Carcinoma
- 31 December 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 83 (3) , 485-490
- https://doi.org/10.1006/gyno.2001.6429
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial PrecancersJNCI Journal of the National Cancer Institute, 2000
- Minimal Uterine Serous CarcinomaThe American Journal of Surgical Pathology, 2000
- The frequency of p53, k-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinomaCancer, 2000
- Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinomaPublished by Wiley ,2000
- p53 Immunostaining as a Significant Adjunct Diagnostic Method for Uterine Surface CarcinomaThe American Journal of Surgical Pathology, 1998
- High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assayOncogene, 1997
- p53 Overexpression and bcl-2 Persistence in Endometrial Carcinoma: Comparison of Papillary Serous and Endometrioid SubtypesGynecologic Oncology, 1996
- p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesisHuman Pathology, 1995
- A simple p53 functional assay for screening cell lines, blood, and tumors.Proceedings of the National Academy of Sciences, 1995
- Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrenceCancer, 1993